Use of alpha-glutamyl-tryptophan in patients with chronic atrophic autoimmune gastritis: interim study results

Objective. To analyze clinical outcomes in patients over 18 years of age receiving alpha-glutamyl-tryptophan for autoimmune atrophic gastritis (AAG). Material and methods. Ten patients diagnosed with chronic AAG were enrolled and prescribed alpha-glutamyl-tryptophan («Regastim Gastro», oral gel powder). The study followed a prospective before-and-after design. After two of four planned therapy courses, interim results were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and a Likert scale evaluating treatment satisfaction. Adverse events were monitored. Results. Based on the GSRS, four of nine patients reported significant symptom reduction (>10 points), two showed minor improvement (1—2 points), and three had no changes. According to the Likert scale, all patients noted some degree of improvement, with five indicating marked relief. One underweight female patient gained weight during therapy. Alpha-glutamyl-tryptophan had no adverse effect on the efficacy or dosing of concomitant medications. Two patients reported self-limiting diarrhea during the first two days of treatment, and one experienced mild, transient epigastric and periumbilical discomfort during the first five days. These effects resolved without intervention or treatment discontinuation. Conclusion. After two courses of alpha-glutamyl-tryptophan therapy, patients with autoimmune atrophic gastritis demonstrated good treatment tolerability, symptomatic improvement, enhanced quality of life, and no negative interactions with other medications.